After a first generation ARM-U1 compound, containing uPA itself as the TBM [256], the authors synthesized a second-generation ARM, named ARM-U2, combining a restructured analog of IPR-803, a previously identified high-affinity uPAR inhibitor, as the TBM, and a 2,4-dinitrophenol (DNP) moiety as the ABM, to exploit the naturally occurring anti-DNP antibodies for cancer cell destruction [257]. Here, PLAUR is linked to cancer.